The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 54 results:
Author Title Type [ Year(Asc)]
Filters: Author is Bekiari, Eleni  [Clear All Filters]
2018
Papatheodorou, K., Banach M., Bekiari E., Rizzo M., & Edmonds M. (2018).  Complications of Diabetes 2017.. J Diabetes Res. 2018, 3086167.
Bekiari, E., Karagiannis T., & Tsapas A. (2018).  In type 2 diabetes, weekly semaglutide reduced HbA 1c and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine. 168(8), JC46.
Bekiari, E., Karagiannis T., & Tsapas A. (2018).  In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.. Ann Intern Med. 168(8), JC46.
Andreadis, P., Karagiannis T., Malandris K., Avgerinos I., Liakos A., Manolopoulos A., et al. (2018).  Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.. Diabetes Obes Metab. 20(9), 2255-2263.
Andreadis, P., Karagiannis T., Malandris K., Avgerinos I., Liakos A., Manolopoulos A., et al. (2018).  Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism.
2017
Tziomalos, K., Gkougkourelas I., Sarantopoulos A., Bekiari E., Makri E., Raptis N., et al. (2017).  Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus.. Rheumatol Int. 37(2), 293-298.
Mainou, M., Madenidou A-V., Liakos A., Paschos P., Karagiannis T., Bekiari E., et al. (2017).  Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.. Eur J Haematol. 98(6), 563-568.
Mainou, M., Madenidou A-V., Liakos A., Paschos P., Karagiannis T., Bekiari E., et al. (2017).  Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. European Journal of Haematology. 98111125151171328622526459851317339343312102118301141312212432349259292117201512520158233100(6), 563 - 568.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.. Core Evid. 12, 1-10.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence. Volume 12, 1 - 10.
Liakopoulou, P., Liakos A., Vasilakou D., Athanasiadou E., Bekiari E., Kazakos K., et al. (2017).  Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.. Endocrine. 56(3), 485-494.
Liakopoulou, P., Liakos A., Vasilakou D., Athanasiadou E., Bekiari E., Kazakos K., et al. (2017).  Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. Endocrine. 5625815134372239371731583439396341596(31134341111109129114943), 485 - 494.
Bekiari, E., Karagiannis T., Haidich A-B., & Tsapas A. (2017).  Meta-analysis of artificial pancreas trials: methodological considerations. The Lancet Diabetes & Endocrinology. 5(9), 685.
Bekiari, E., Karagiannis T., Haidich A-B., & Tsapas A. (2017).  Meta-analysis of artificial pancreas trials: methodological considerations.. Lancet Diabetes Endocrinol. 5(9), 685.
Stoimenis, D., Karagiannis T., Katsoula A., Athanasiadou E., Kazakos K., Bekiari E., et al. (2017).  Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.. Expert Opin Pharmacother. 18(9), 843-851.
Stoimenis, D., Karagiannis T., Katsoula A., Athanasiadou E., Kazakos K., Bekiari E., et al. (2017).  Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy. 18555857646565(9111111), 843 - 851.
2016
Rizava, C., Bekiari E., Liakos A., Sarigianni M., Rika M., Haidich A. Bettina, et al. (2016).  Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. Endocrine. 541493253564319603435853315343646323232332378366375452107937693091093863(331029229844492951104144411978855372514249), 620 - 633.
Karagiannis, T., Bekiari E., Boura P., & Tsapas A. (2016).  Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.. Ther Adv Drug Saf. 7(2), 36-8.
Karagiannis, T., Bekiari E., Boura P., & Tsapas A. (2016).  Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
Karagiannis, T., & Bekiari E. (2016).  Most add-on therapies to metformin have similar effects on HbA1c.. Evid Based Med. 21(6), 223.
Tsapas, A., Karagiannis T., & Bekiari E. (2016).  Premixed insulin regimens for type 2 diabetes. Endocrine. 5128136293852682932172681092030295868(321Suppl 2811036512641555321), 387 - 389.
Bekiari, E., Rizava C., Athanasiadou E., Papatheodorou K., Liakos A., Karagiannis T., et al. (2016).  Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine. 458 - 480.
2015
Liakos, A., Athanasiadou E., Mainou M., Bekiari E., Haidich A. Bettina, Rizos E. C., et al. (2015).  Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.. Ann Intern Med. 163(3), 241.
Liakos, A., Karagiannis T., Bekiari E., Boura P., & Tsapas A. (2015).  Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.. Ther Adv Endocrinol Metab. 6(2), 61-7.
2014
Tsapas, A., Liakos A., Paschos P., Karagiannis T., Bekiari E., Tentolouris N., et al. (2014).  A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis.. Metabolism. 63(4), 584-92.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.